Physician profile
Mary H Ward
NPI 1083687206
$6,274.07
in general payments reported to CMS, 2019-2025
33 companies · $26.93 in 2025
The $26.93 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,157 · 2020: $513 · 2021: $2,797 · 2022: $1,247 · 2023: $432 · 2024: $100 · 2025: $26.93.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $560.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $559.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $1,244.59 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $750.85 | 2019-2023 | Farxiga, Breztri |
| Glaxosmithkline, LLC. | $709.45 | 2019-2023 | Trelegy Ellipta, Shingrix |
| Lilly USA, LLC | $688.54 | 2019-2024 | Zepbound, Mounjaro, Jardiance |
| Novo Nordisk INC | $511.70 | 2019-2023 | Rybelsus, Ozempic |
| Pfizer INC. | $402.91 | 2019-2023 | |
| Abbvie INC. | $332.04 | 2019-2023 | Ubrelvy |
| Amarin Pharma, INC. | $203.08 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $186.79 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $156.84 | 2020-2022 | |
| Dexcom, INC. | $126.54 | 2021-2023 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $123.84 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $98.40 | 2019-2022 | |
| Eisai INC. | $83.58 | 2021 | |
| Amgen INC. | $78.57 | 2020-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $78.04 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $67.42 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $48.53 | 2021-2023 | |
| Astellas Pharma US INC | $41.80 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $38.23 | 2021 | |
| Upsher-Smith Laboratories LLC | $36.29 | 2022 | |
| Ironwood Pharmaceuticals, INC | $35.44 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $32.09 | 2019 | |
| Jazz Pharmaceuticals INC. | $30.97 | 2021 | |
| Exact Sciences Corporation | $26.93 | 2025 | Cologuard Collection Kit |
| Alk-Abello, INC | $23.12 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $21.05 | 2023 | Rexulti |
| Si-Bone, INC. | $19.69 | 2023 | |
| Sanofi Pasteur INC. | $18.23 | 2022 | |
| Allergan, INC. | $16.95 | 2020 | |
| Sanofi-Aventis U.S. LLC | $14.50 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.14 | 2019 | |
| Ge Healthcare | $12.93 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Ward listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.